Form 13-F position report

COGNITION THERAPEUTICS INC

Reported by COMMONWEALTH EQUITY SERVICES LLC

CGTX CUSIP 19243B102 Manager CIK 0000312272

Reported 168,692 shares, down 20,615 (10.9%) from the prior quarter.

Reported value -15.9%; share count -10.9% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q1 2023
Shares 168,692 Quarter-end amount reported
Reported value $334,000 Fair value at quarter end
Consecutive quarters held 5 Through Q1 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2022-03-31 38000
2022-06-30 453000
2022-09-30 416000
2022-12-31 397000
2023-03-31 334000
2023-06-30 171000
2023-09-30 134000
2023-12-31 172000
2024-03-31 169000
2024-06-30 151000
2024-09-30 42000
2024-12-31 64000
2025-03-31 18000
2025-06-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

14 quarters
Quarterly reported position history for COGNITION THERAPEUTICS INC held by COMMONWEALTH EQUITY SERVICES LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2025 Reduced 0 -41,665 (-100.0%) 0 $0 2025-08-06
Q1 2025 Reduced 41,665 -49,000 (-54.0%) < 0.01% $18,000 2025-05-09
Q4 2024 Unchanged 90,665 0 (0.0%) < 0.01% $64,000 2025-02-10
Q3 2024 Unchanged 90,665 0 (0.0%) < 0.01% $42,000 2024-10-18
Q2 2024 Reduced 90,665 -2,000 (-2.2%) < 0.01% $151,000 2024-07-31
Q1 2024 Reduced 92,665 -65 (-0.1%) < 0.01% $169,000 2024-04-29
Q4 2023 Unchanged 92,730 0 (0.0%) < 0.01% $172,000 2024-02-06
Q3 2023 Reduced 92,730 -505 (-0.5%) < 0.01% $134,000 2023-10-23
Q2 2023 Reduced 93,235 -75,457 (-44.7%) < 0.01% $171,000 2023-08-10
Q1 2023 Reduced 168,692 -20,615 (-10.9%) < 0.01% $334,000 2023-05-11
Q4 2022 Reduced 189,307 -29,762 (-13.6%) < 0.01% $397,000 2023-02-07
Q3 2022 Added 219,069 +4,108 (1.9%) < 0.01% $416,000 2022-11-14
Q2 2022 Added 214,961 +201,071 (1447.6%) < 0.01% $453,000 2022-07-19
Q1 2022 New 13,890 +13,890 (0.0%) < 0.01% $38,000 2022-05-04

Who else reported the position

38 managers reported COGNITION THERAPEUTICS INC for Q1 2023.

Managers reporting COGNITION THERAPEUTICS INC in Q1 2023.
Manager Activity Shares Change % of reported 13F Reported value Tenure
PATHSTONE FAMILY OFFICE LLC Unchanged 2,210,377 0 0.07% $4,376,546 4 qtrs
AIGH Capital Management LLC Unchanged 2,037,853 0 1.49% $4,034,949 6 qtrs
VANGUARD GROUP INC Added 643,390 +98,501 < 0.01% $1,273,912 6 qtrs
Worth Venture Partners LLC Unchanged 501,719 0 0.48% $993,404 5 qtrs
CARLSON CAPITAL L P Added 245,169 +15,269 0.05% $485,435 3 qtrs
Perigon Wealth Management LLC Reduced 225,000 -1,000 0.03% $445,500 4 qtrs
AMERICAN FINANCIAL GROUP INC Unchanged 205,000 0 0.13% $406,000 6 qtrs
COMMONWEALTH EQUITY SERVICES LLC This report Reduced 168,692 -20,615 < 0.01% $334,000 5 qtrs
Voss Capital LLC Reduced 159,973 -6,930 0.04% $316,747 6 qtrs
GEODE CAPITAL MANAGEMENT LLC Unchanged 122,598 0 < 0.01% $242,744 5 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2023
Filed
May 11, 2023
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
0
Shared
0
None
168,692

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.